Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Invesco DB Oil Fund (DBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Invesco DB Oil Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Invesco DB Oil Fund trades at $18.6. The key difference: Invesco DB Oil Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DBO | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Commodities - Energy |
52-Week High | $491.22 | $23.80 |
52-Week Low | $278.09 | $11.98 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DBO trades at $18.06, down 0.44% with neutral technical signals amid volatile oil market conditions. The stock shows bearish moving averages but neutral oscillators, with key support at $18 and resistance at $19. Recent oil price volatility driven by geopolitical tensions creates both opportunities and risks for energy sector stocks.
The outlook remains balanced with oil market fundamentals showing mixed signals - supply constraints from geopolitical events versus potential demand concerns. Investment opportunity exists if oil prices sustain recent gains, while risks include Middle East volatility and potential demand deterioration. The stock's technical positioning suggests range-bound trading near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →
